RxDoctor Payments Data

Derek Ohlstein, MD

Ophthalmology · Vero Beach, FLNPI 1295960946

Payments from drug & device makers

$4,660in general payments, 2019–2025

Across 185 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$621
  • Johnson & Johnson Surgical Vision, Inc.$420
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$395
  • AbbVie$381
  • Shire North American Group Inc$337
  • Ocular Therapeutix, Inc.$299
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$2986%
  • Food & beverage$4,36294%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,660 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$711,131
Medicare patients
1,634
Services billed
6,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine47$42,477
LumiganBimatoprost61$33,668
CombiganBrimonidine Tartrate/Timolol33$15,147
RhopressaNetarsudil Mesylate20$12,927
MieboPerfluorohexyloctane/Pf17$12,709
AlrexLoteprednol Etabonate41$11,595
Loteprednol Etabonate60$11,571
VyzultaLatanoprostene Bunod24$9,819
Tobramycin-DexamethasoneTobramycin/Dexamethasone245$7,165
Latanoprost481$5,634
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol39$5,465
Alphagan PBrimonidine Tartrate13$5,117
SimbrinzaBrinzolamide/Brimonidine Tart21$5,008
Prednisolone Acetate103$4,994
Travoprost15$3,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$381$96,409154 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Loteprednol Etabonate$395$23,166101 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$252$22,52941 claims
Aerie Pharmaceuticals, Inc.Rhopressa$70$12,92720 claims
AlconSimbrinza$621$5,00821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →